A collective mobilization to promote international visibility
With ALPX, Antelope Therapeutics, ANTINEO, AUROBAC THERAPEUTICS, Axoltis Pharma, Brenus Pharma, COVALAB, CYTOO, Dillico, ErVimmune, Eurofins Optimed Clinical Research, HEPHAISTOS-Pharma, Lys Therapeutics and NETRI, the delegation took advantage of this event to engage in numerous discussions with potential partners, identify opportunities for collaboration and raise their profile amongst leading international players.
A highlight of the global life sciences calendar, the BIO International Convention serves as a key driver for accelerating the development of innovative companies. It provides an ideal setting for engaging in strategic discussions, establishing partnerships and fostering international cooperation. With this in mind, the cluster’s on-site team also helped to promote emerging projects from the region to international partners on behalf of the SATT Linksium, thereby strengthening the links between academic research and industry players.
Furthermore, Lyonbiopole took part in the Global Innovation Hub to showcase French excellence in health innovation and promote the expertise of the regional ecosystem to a qualified international audience.
This year’s event took on particular significance in the run-up to hosting BIO-Europe Spring® in Lyon next April. It thus helped to raise the profile of regional stakeholders, consolidate initial contacts made at the event, and actively prepare for this major event by showcasing the strengths and dynamism of the Auvergne-Rhône-Alpes health innovation ecosystem.
